“CAR-T cell development is expensive and patient-derived tissue is a limited resource. Our aim is to enable 20 to 50 times more experiments to be performed in these conditions.” – Dr M Zagnoni, CEO of Screenin3D
Miniaturisation and increased throughput in screening are key to a faster, more cost-effective delivery of cancer therapies from bench to bedside. In a new publication in IEEE Open Journal of Engineering in Medicine and Biology, Screenin3D OncoChip3D microfluidic platform was used to test the cytotoxicity of CAR-T cells and combination therapy on miniaturised solid cancer models.
In this publication, the technology showcases a co-culture of cancerous and stromal cells that create a physiologically relevant solid cancer model for the assessment of CAR-T, carboplatin, and anti-PD-L1 antibody therapies.